Figure 4 | Scientific Reports

Figure 4

From: Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study

Figure 4

Comparison of best-corrected visual acuity (BCVA) changes from baseline at different time points, split according to treatment response at month 3. The patients were divided into 3 groups according to the BCVA change at Month 3: strong improvement (change in logMAR BCVA ≤−0.2), limited improvement (change in logMAR BCVA ≤0 to >−0.2), and no improvement (change in logMAR BCVA >0). At months 3, 6, and 12 the BCVA improvement was significantly better in the strong improvement group than in the limited improvement group, and both were significantly better than in the no-improvement group (P < 0.001 for all comparisons).

Back to article page